These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New insights into the older hypoglycemic agents in type 2 diabetes therapy. Cao M; Bloomgarden Z J Diabetes; 2020 Nov; 12(11):844-847. PubMed ID: 32767624 [No Abstract] [Full Text] [Related]
5. Combined therapy with insulin plus oral agents: is there any advantage? An argument in favor. Riddle MC Diabetes Care; 2008 Feb; 31 Suppl 2():S125-30. PubMed ID: 18227472 [No Abstract] [Full Text] [Related]
6. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group. Ann Intern Med; 1998 Feb; 128(3):165-75. PubMed ID: 9454524 [TBL] [Abstract][Full Text] [Related]
7. Early insulin use in type 2 diabetes: what are the cons? Chiasson JL Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S270-4. PubMed ID: 19875563 [No Abstract] [Full Text] [Related]
8. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Kiayias JA; Vlachou ED; Theodosopoulou E; Lakka-Papadodima E Diabetes Care; 2002 Jul; 25(7):1251-2. PubMed ID: 12087036 [No Abstract] [Full Text] [Related]
9. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with meformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea: response to Barnett et al. Mikhail N; Cope D Diabetes Care; 2006 Oct; 29(10):2332-3; author reply 2333. PubMed ID: 17003325 [No Abstract] [Full Text] [Related]
10. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. Arnolds S; Rave K Lancet; 2008 Aug; 372(9636):370-1; author reply 372. PubMed ID: 18675680 [No Abstract] [Full Text] [Related]
11. Clinical experience with exenatide in a routine secondary care diabetes clinic. Natarajan B; Edavalath M; Davies J; Jenkins L; Marshall-Richards N; Evans D; Price DE; Bain SC; Stephens JW Prim Care Diabetes; 2010 Apr; 4(1):57-60. PubMed ID: 20022310 [TBL] [Abstract][Full Text] [Related]
12. A summary of the ADVANCE Trial. Heller SR; Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S357-61. PubMed ID: 19875581 [No Abstract] [Full Text] [Related]
13. Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267. Home PD Diabetologia; 2007 Jul; 50(7):1561-2; author reply 1563-4. PubMed ID: 17384924 [No Abstract] [Full Text] [Related]
14. Are you up-to-date on diabetes medications? Scemons D Nursing; 2007 Jul; 37(7):45-9; quiz 49-50. PubMed ID: 17603373 [TBL] [Abstract][Full Text] [Related]
15. Serum C-peptide levels determine glycemic responses in type II diabetic patients treated with combined insulin and sulfonylurea agent. Osei K; Falko JM Am J Med Sci; 1985 Apr; 289(4):148-53. PubMed ID: 3920907 [TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Dills DG; Schneider J Horm Metab Res; 1996 Sep; 28(9):426-9. PubMed ID: 8911977 [TBL] [Abstract][Full Text] [Related]
17. Investigation of the introduction of three times daily injections of Insulin Lispro Mixture-50 on an outpatient basis: therapeutic effects of 12 months' treatment with and without concomitant sulfonylurea. Suzuki K; Morikawa H; Iwanaga M; Aizawa Y J Diabetes; 2012 Sep; 4(3):262-3. PubMed ID: 22325575 [No Abstract] [Full Text] [Related]
18. (7) Approaches to glycemic treatment. American Diabetes Association Diabetes Care; 2015 Jan; 38 Suppl():S41-8. PubMed ID: 25537707 [No Abstract] [Full Text] [Related]